CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP has issued a solicitation for lead plaintiffs in a class action lawsuit against Capricor Therapeutics regarding alleged securities fraud. The complaint alleges the company made misleading statements about changing the statistical analysis plan for Deramiocel’s Biologics License Application without prior FDA agreement, posing a risk of non-approval.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.